The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Update: New Boxed Warnings for Opioids & Benzodiazepines; Plus New Drug Safety Labeling Changes Database

FDA Update: New Boxed Warnings for Opioids & Benzodiazepines; Plus New Drug Safety Labeling Changes Database

October 5, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270FDA Adds Boxed Warnings to Opioids & Benzodiazepines
The U.S. Food and Drug Administration (FDA) conducted two studies and evaluated two additional studies on the risks of combining opioids used to treat pain/cough and benzodiazepines.1 These studies showed an increasing trend in concomitant dispensing of opioid analgesics and benzodiazepines, as well as an increasing frequency of combined benzodiazepine and prescription opioid misuse, abuse and overdose—from prescribed or greater-than-prescribed doses—as measured by national emergency department visits and overdose death rates. Review of these data has led the FDA to conclude that the combined use of opioids and benzodiazepines or other central nervous system (CNS) depressants has resulted in serious side effects, including dyspnea and death. Opioids treat both pain and cough; benzodiazepines have many uses, including the treatment of anxiety, insomnia and seizures.

You Might Also Like
  • FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers
  • FDA Expands Safety Measures for Immediate Release Opioids
  • FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling
Also By This Author
  • Reinitiating TNF Blockers after Tuberculosis Treatment

As a result, the FDA is requiring manufacturers of opioids and benzodiazepines to update the labeling of these products. New Boxed Warnings, the FDA’s strongest warnings, are currently being added to the drug labeling of prescription opioids and benzodiazepines. Related revisions will also be made to the Warnings and Precautions, Drug Interactions, and Patient Counseling Information sections of the labeling.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA is requesting that healthcare professionals limit prescribing opioids in combination with benzodiazepines or other CNS depressants. These combinations should be prescribed only to patients who have no other treatment options. If these medication classes are prescribed together, the dosage and duration of each drug should be limited to the minimum possible amount and shortest time to achieve the desired clinical effect. Patients and caregivers should be warned about the risks to breathing and sedation, as well as their signs and symptoms. If possible, practitioners should avoid prescribing opioids to patients taking benzodiazepines or CNS depressants, as well as those who consume alcohol.

New Drug Safety Labeling Changes Database
On Sept. 1, the FDA debuted its new Drug Safety Labeling Changes (SLC) database.2 Users can search recently FDA-approved drug product labeling changes to safety information by drug name, date range and labeling section. The database has seven searchable labeling sections: boxed warning; contraindications; adverse reactions; warnings and precautions; drug interactions; use in specific populations; and patient counseling information, patient information or Medication Guide. Search the database at www.accessdata.fda.gov/scripts/cder/safetylabelingchanges.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. U.S. Food and Drug Administration. Safety announcement: FDA drug safety communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. 2016 Aug 31.
  2. U.S. Food and Drug Administration. Drug Safety Labeling Changes (SLC) quick reference. 2016 Sep 1.

Pages: 1 2 | Single Page

Filed Under: Analgesics, Drug Updates, Safety Tagged With: benzodiazepines, Drug Safety, Drug Safety Labeling Changes (SLC) database, FDA, Food and Drug Administration, Opioids, safety warning

You Might Also Like:
  • FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers
  • FDA Expands Safety Measures for Immediate Release Opioids
  • FDA Update: FX006 Promising for Knee OA; Pioglitazone Linked to Bladder Cancer Risk; & HIV Drug Gets New Labeling
  • FDA Update: FDA Delays Baricitinib Review & Removes Bupropion & Varenicline Warnings

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)